ARVN

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 6

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,928

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.04 to $80.74, inclusive.

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 5

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,324

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.04 to $79.91, inclusive.

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 4

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,282

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.04 to $79.03, inclusive.

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 188,585

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.04 to $78.035, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (10) to this Form 4.

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,743

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

SEC source: 0000899243-21-007141 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,599

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

SEC source: 0000899243-21-007153 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,320

Underlying: Common Stock · 1,560 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007153 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007136 · doc4.xml · derivative · entry 3

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,184

Underlying: Common Stock · 20,000 shares

Expires 2029-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.

F4 · derivative.exercise_date: This option award was granted on July 29, 2019. 1/4 of the shares underlying the award vested on July 29, 2020, with the remainder of the shares vesting in equal monthly installments following July 29, 2020 through July 29, 2023.

SEC source: 0000899243-21-007136 · doc4.xml · nonDerivative · entry 2

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,754

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.00 to $77.66, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).

SEC source: 0000899243-21-007136 · doc4.xml · nonDerivative · entry 1

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.

SEC source: 0000899243-21-007143 · doc4.xml · derivative · entry 6

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,880

Underlying: Common Stock · 44,000 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F7 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on March 31, 2019, with the remainder of the shares vesting in equal monthly installments following March 31, 2019 through March 31, 2022.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 5

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,200

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.13 to $80.49, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 4

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,800

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.13 to $80.06, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 830,023

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.13 to $79.09, inclusive.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 851,272

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.12 to $78.11, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.

SEC source: 0000899243-21-007143 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 860,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 818,248

F2 · kind: The shares were acquired under the 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F4 · balance_after: Includes an aggregate of 625 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-20-064697 · doc4.xml · nonDerivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 822,857

F1 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-058102 · doc4.xml · nonDerivative · entry 1

Kennedy Edward Moore Jr. · CIK 0001753859 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,718

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.95 to $24.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-20-058093 · doc4.xml · derivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,696

Underlying: Common Stock · 2,356 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-20-058093 · doc4.xml · derivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,517

Underlying: Common Stock · 650 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022.

SEC source: 0001209191-20-058093 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-028308 · doc4.xml · nonDerivative · entry 1

Canaan IX L.P. · CIK 0001538676 · 10% owner

Canaan Partners IX LLC · CIK 0001654586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,589,554

F1 · kind: On October 14, 2020, Canaan IX L.P. (the "Canaan Fund") distributed, for no consideration, 400,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners IX LLC ("Canaan IX" and, together with the Canaan Fund, the "Canaan Entities"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On October 14, 2020, Canaan IX L.P. (the "Canaan Fund") distributed, for no consideration, 400,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners IX LLC ("Canaan IX" and, together with the Canaan Fund, the "Canaan Entities"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: The shares are held directly by the Canaan Fund. Canaan IX is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001209191-20-047315 · doc4.xml · derivative · entry 3

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,031

Underlying: Common Stock · 4,010 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: On July 29, 2019, the reporting person was granted 16,041 Restricted Stock Units, vesting in four equal annual installments beginning July 29, 2020.

F3 · derivative.expiration_date: On July 29, 2019, the reporting person was granted 16,041 Restricted Stock Units, vesting in four equal annual installments beginning July 29, 2020.

SEC source: 0001209191-20-047315 · doc4.xml · nonDerivative · entry 2

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,754

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

SEC source: 0001209191-20-047315 · doc4.xml · nonDerivative · entry 1

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-20-019796 · doc4.xml · nonDerivative · entry 1

Canaan IX L.P. · CIK 0001538676 · 10% owner

Canaan Partners IX LLC · CIK 0001654586 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,989,554

F1 · kind: On July 20, 2020, Canaan IX L.P. (the "Canaan Fund") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners IX LLC ("Canaan IX" and, together with the Canaan Fund, the "Canaan Entities"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: On July 20, 2020, Canaan IX L.P. (the "Canaan Fund") distributed, for no consideration, 500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners IX LLC ("Canaan IX" and, together with the Canaan Fund, the "Canaan Entities"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan IX distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: The shares are held directly by the Canaan Fund. Canaan IX is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan IX disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000899243-21-009196 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817,938

F2 · kind: The shares were acquired under the 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F3 · balance_after: Includes 315 shares acquired under the 2018 Employee Stock Purchase Plan.

SEC source: 0001209191-20-039888 · doc4.xml · derivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-06-28

F1 · derivative.exercise_date: This option award was granted on June 29, 2020. The shares underlying the award shall vest in equal monthly installments through June 29, 2023.

SEC source: 0001209191-20-037980 · doc4.xml · nonDerivative · entry 1

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,546

F1 · balance_after: Includes shares received by the Reporting Person in a prior distribution.

SEC source: 0001209191-20-036363 · doc4.xml · derivative · entry 1

Bain Linda · CIK 0001578407 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2030-06-09

F1 · derivative.exercise_date: This option award was granted on June 10, 2020. The shares underlying the award shall vest in equal monthly installments through June 10, 2023.

SEC source: 0001209191-20-034585 · doc4.xml · derivative · entry 1

Kennedy Edward Moore Jr. · CIK 0001753859 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034590 · doc4.xml · derivative · entry 3

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F4 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034583 · doc4.xml · derivative · entry 1

Norwalk Leslie V · CIK 0001533568 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034584 · doc4.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034586 · doc4.xml · derivative · entry 1

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034588 · doc4.xml · derivative · entry 1

Morrison Briggs · CIK 0001654430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034589 · doc4.xml · derivative · entry 1

Margus Bradley Albert · CIK 0001753491 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034587 · doc4.xml · derivative · entry 1

Loven Jakob · CIK 0001753644 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2030-06-02

F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-20-034590 · doc4.xml · nonDerivative · entry 1

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,546

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.20 to $32.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

F2 · balance_after: Includes shares received by the Reporting Person in a prior distribution.

SEC source: 0001209191-20-032172 · doc4.xml · derivative · entry 3

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,923 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020.

SEC source: 0001209191-20-032172 · doc4.xml · nonDerivative · entry 1

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes shares received by the Reporting Person in a prior distribution.

SEC source: 0001209191-20-032410 · doc4.xml · derivative · entry 3

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,423

Underlying: Common Stock · 6,500 shares

Expires 2029-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020.

SEC source: 0001209191-20-032410 · doc4.xml · nonDerivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-029414 · doc4.xml · derivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,052

Underlying: Common Stock · 1,139 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-20-029414 · doc4.xml · derivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,167

Underlying: Common Stock · 217 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022.

SEC source: 0001209191-20-029414 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,778

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-029413 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,422

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

SEC source: 0001209191-20-021125 · doc4.xml · nonDerivative · entry 1

Morrison Briggs · CIK 0001654430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,520

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.04 to $38.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.